Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
Nature Medicine2005Vol. 11(11), pp. 1170–1172
Citations Over TimeTop 1% of 2005 papers
Gerd Fätkenheuer, Anton Pozniak, Margaret Johnson, Andreas Plettenberg, Schlomo Staszewski, Andy I. M. Hoepelman, Michael S. Saag, Frank D. Goebel, Jürgen K. Rockstroh, Bruce J. Dezube, T.M. Jenkins, Christine G. Medhurst, John Sullivan, Caroline E. Ridgway, Sylvie Abel, Ian James, Mike Youle, Elna van der Ryst
Related Papers
- → Rapamycin enhances aplaviroc anti-HIV activity: Implications for the clinical development of novel CCR5 antagonists(2009)15 cited
- → New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists(2008)15 cited
- → Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention(2011)12 cited
- → Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients(2010)2 cited